503A vs. 503B Pharmacy: What Compounds Your GLP-1 Medication?

When a telehealth provider prescribes you compounded semaglutide or tirzepatide, the medication is prepared by a compounding pharmacy. But not all compounding pharmacies operate under the same rules. The two main categories — 503A and 503B — differ significantly in regulatory oversight, testing requirements, and what they're legally allowed to do. Here's what that means for the medication you're receiving.

503A Compounding Pharmacies

503A pharmacies are traditional compounding pharmacies regulated primarily by their state board of pharmacy. They operate under Section 503A of the Federal Food, Drug, and Cosmetic Act.

What they do: Compound medications for individual patients based on specific prescriptions. Each batch is made for one patient's prescription. They're the pharmacist mixing your specific medication per your doctor's order.

Regulatory oversight: State board of pharmacy inspections. Must follow USP <797> standards for sterile compounding (guidelines for contamination prevention, environmental monitoring, and personnel training). Not directly regulated by the FDA in most circumstances.

Testing requirements: Batch testing is not universally mandated. Requirements vary by state. Some 503A pharmacies voluntarily test every batch; others test periodically or only when required by state regulations. There is no federal requirement for potency or sterility testing on every batch.

Scale: Patient-specific. A 503A pharmacy compounds your individual prescription. They cannot mass-produce medications "in anticipation of" prescriptions (with limited exceptions).

503B Outsourcing Facilities

503B facilities are a newer category created by the Drug Quality and Security Act (DQSA) of 2013, following the deadly 2012 meningitis outbreak caused by the New England Compounding Center. They operate under direct FDA oversight.

What they do: Compound medications at larger scale. They can produce batches without patient-specific prescriptions and distribute to healthcare practitioners and hospitals. Think of them as a step between traditional pharmacies and pharmaceutical manufacturers.

Regulatory oversight: Registered with the FDA. Subject to FDA inspection using current Good Manufacturing Practice (cGMP) standards — the same quality framework that brand-name drug manufacturers follow. This includes facility design, personnel qualifications, production controls, and record-keeping requirements.

Testing requirements: Mandatory batch testing for potency and sterility on every batch before release. This is the critical differentiator — you know that every vial leaving a 503B facility has been tested to contain the labeled amount of active ingredient and is sterile.

Scale: Can compound in bulk. This is why 503B facilities can supply telehealth platforms with thousands of patients — they're built for volume production with pharmaceutical-grade controls.

Side-by-Side Comparison

Does the Pharmacy Type Affect Your Medication?

The active ingredient is the same. Whether compounded by a 503A or 503B facility, the semaglutide or tirzepatide you receive contains the same active pharmaceutical ingredient (API). The difference is in the quality controls applied during production.

Potency consistency matters. FDA testing of compounded GLP-1 products has found variability. Some samples contained less active ingredient than labeled; a small number contained more. 503B facilities' mandatory batch testing makes potency deviations far less likely — every batch is tested before it ships. With 503A pharmacies, potency testing practices vary widely.

Sterility is non-negotiable. Injectable medications must be sterile. Both 503A and 503B facilities are required to follow sterile compounding practices. But 503B facilities face more rigorous documentation and testing requirements, and FDA inspection adds an enforcement layer that state boards may not provide as consistently.

How to Check Your Provider's Pharmacy

Most telehealth providers don't prominently advertise which type of pharmacy they use. Here's how to find out:

Ask directly. Any legitimate provider should tell you whether their pharmacy partner is 503A or 503B. If they refuse to answer or say they "can't disclose," that's a red flag.

Check the FDA's 503B registry. The FDA maintains a public list of registered outsourcing facilities at fda.gov. If a provider claims to use a 503B pharmacy, you can verify it.

Look for PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) provides voluntary accreditation for compounding pharmacies. It's not a guarantee of quality, but it signals that a 503A pharmacy has submitted to third-party review of their practices.

Why This Matters More in 2026

The FDA's March 2026 warning letters to GLP-1 telehealth companies specifically flagged concerns about compounding pharmacy quality. As regulatory scrutiny increases, the distinction between 503A and 503B becomes more important — not less. Patients who understand the difference can make informed choices about their provider and ask the right questions before receiving medication.

No matter which pharmacy type your provider uses, the minimum verification checklist is the same: confirm the pharmacy is licensed in your state, ask whether they test every batch for potency and sterility, and verify that the telehealth platform has a way for you to report adverse events if anything goes wrong.